A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...

UroGen Pharma faces a pivotal period as ZUSDURI, its recently approved bladder cancer therapy, is positioned for accelerated adoption following a permanent J-Code in 2026. ZUSDURI's peak sales are ...

Use of multiparametric MRI for the initial staging of suspected MIBC shortened the time to correct treatment compared with TURBT. Incorporating multiparametric MRI (mpMRI) into the initial staging of ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...

Neoadjuvant cisplatin-based chemotherapy plus chemoradiotherapy offers a safe, effective bladder-sparing approach with promising long-term outcomes in nonmetastatic MIBC. Median disease-free survival ...

Bipolar transurethral resection represents a significant evolution in the surgical management of bladder cancer, particularly for non‐muscle invasive bladder cancer (NMIBC). This technique utilises an ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...